Abrocitinib: A panacea for atopic dermatitis

Atopic Dermatitis [AD] is a chronic relapsing inflammatory dermatological disease characterized by itch, dry skin, localized or disseminated eczematous lesions and hyperpigmentation of skin. There are several exogeneous endogenous risk factors for development AD. The include genetic factors, atopy, skin hyperreactivity such as food, dust, pollen, epidermal, fungal, bacterial, vaccine-associated factors. management AD includes topical treatments corticosteroids, capsaicin, calcineurin inhibitors phosphodiesterase inhibitors. Systemic therapies immunosuppressants, biologicals, gabapentinoids antidepressants provided to patients with inadequate systemic have wide range side effects limiting their use in many patients. Therefore, there need innovative treatment options. This led Janus kinase First generation JAK Tofacitinib, Baricitinib, Ruxolitinib, Oclacitinib. Second drugs Upadacitinib Abrocitinib more specific towards the isoforms. review addresses importance Abrocitinb Dermatitis. an oral once daily moderate severe atopic dermatitis developed Pfizer. Studies shows that better alternative non- responders Dupilumab therapy contraindications Dupilumab. patient’s adherence medication will also be route rather than injections. widely accepted because its clinical benefits reduction itching convenient administration.